Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.

Goodyear CS, Patel A, Barnes E, Willicombe M, Siebert S, de Silva TI, Snowden JA, Lim SH, Bowden SJ, Billingham L, Richter A, Carroll M, Carr EJ, Beale R, Rea D, Parry H, Pirrie S, Lim Z, Satsangi J, Dunachie SJ, Cook G, Miller P, Basu N, Gilmour A, Hodgkins AM, Evans L, Hughes A, Longet S, Meacham G, Yong KL, A'Hearne MJ, Koh MBC, Burns SO, Orchard K, Paterson C, McIlroy G, Murray SM, Thomson T, Dimitriadis S, Goulston L, Miller S, Keillor V, Prendecki M, Thomas D, Kirkham A, McInnes IB, Kearns P, OCTAVE-DUO investigators

Open source

DOI
10.1016/s2665-9913(24)00065-1
Published
2024 Jun
Container
The Lancet. Rheumatology
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/s2665-9913-24-00065-1,
  title = {Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.},
  author = {Goodyear CS and Patel A and Barnes E and Willicombe M and Siebert S and de Silva TI and Snowden JA and Lim SH and Bowden SJ and Billingham L and Richter A and Carroll M and Carr EJ and Beale R and Rea D and Parry H and Pirrie S and Lim Z and Satsangi J and Dunachie SJ and Cook G and Miller P and Basu N and Gilmour A and Hodgkins AM and Evans L and Hughes A and Longet S and Meacham G and Yong KL and A'Hearne MJ and Koh MBC and Burns SO and Orchard K and Paterson C and McIlroy G and Murray SM and Thomson T and Dimitriadis S and Goulston L and Miller S and Keillor V and Prendecki M and Thomas D and Kirkham A and McInnes IB and Kearns P and OCTAVE-DUO investigators},
  year = {2024},
  journal = {The Lancet. Rheumatology},
  doi = {10.1016/s2665-9913(24)00065-1},
  url = {https://doi.org/10.1016/s2665-9913(24)00065-1}
}

RIS

TY  - JOUR
TI  - Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.
AU  - Goodyear CS
AU  - Patel A
AU  - Barnes E
AU  - Willicombe M
AU  - Siebert S
AU  - de Silva TI
AU  - Snowden JA
AU  - Lim SH
AU  - Bowden SJ
AU  - Billingham L
AU  - Richter A
AU  - Carroll M
AU  - Carr EJ
AU  - Beale R
AU  - Rea D
AU  - Parry H
AU  - Pirrie S
AU  - Lim Z
AU  - Satsangi J
AU  - Dunachie SJ
AU  - Cook G
AU  - Miller P
AU  - Basu N
AU  - Gilmour A
AU  - Hodgkins AM
AU  - Evans L
AU  - Hughes A
AU  - Longet S
AU  - Meacham G
AU  - Yong KL
AU  - A'Hearne MJ
AU  - Koh MBC
AU  - Burns SO
AU  - Orchard K
AU  - Paterson C
AU  - McIlroy G
AU  - Murray SM
AU  - Thomson T
AU  - Dimitriadis S
AU  - Goulston L
AU  - Miller S
AU  - Keillor V
AU  - Prendecki M
AU  - Thomas D
AU  - Kirkham A
AU  - McInnes IB
AU  - Kearns P
AU  - OCTAVE-DUO investigators
PY  - 2024
JO  - The Lancet. Rheumatology
DO  - 10.1016/s2665-9913(24)00065-1
UR  - https://doi.org/10.1016/s2665-9913(24)00065-1
ER  -

APA

CS, G., A, P., E, B., M, W., S, S., TI, D. S., JA, S., SH, L., SJ, B., L, B., A, R., M, C., EJ, C., R, B., D, R., H, P., S, P., Z, L., J, S., SJ, D., G, C., P, M., N, B., A, G., AM, H., L, E., A, H., S, L., G, M., KL, Y., MJ, A., MBC, K., SO, B., K, O., C, P., G, M., SM, M., T, T., S, D., L, G., S, M., V, K., M, P., D, T., A, K., IB, M., P, K., & investigators, O. (2024). Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.. The Lancet. Rheumatology. https://doi.org/10.1016/s2665-9913(24)00065-1

Source records